安徽宏宇五洲医疗器械股份有限公司 2025年第一季度报告

Group 1 - The company guarantees the authenticity, accuracy, and completeness of the information disclosed in the quarterly report, with no false records, misleading statements, or significant omissions [1][2][8] - The board of directors and supervisory board confirm the quarterly report's compliance with legal and regulatory requirements, reflecting the company's financial status, operating results, and cash flow accurately [10][18] - The first quarter report has not been audited [7][11] Group 2 - The third board of directors' eighth meeting was held on April 25, 2025, with all seven directors present, complying with legal and regulatory requirements [9] - The meeting approved the proposal regarding the first quarter report, confirming its adherence to relevant regulations and accurate reflection of the company's financial situation [10][18] - The voting results for the board meeting were unanimous, with all votes in favor [12] Group 3 - The company will hold the 2024 annual shareholders' meeting on May 15, 2025, using a combination of on-site and online voting [22][24] - The meeting's legal compliance has been confirmed by the board of directors, and all shareholders registered by May 9, 2025, are eligible to attend [23][26] - The meeting will address various proposals, including the independent directors' performance reports [30][32]